Evidence map›Paper›PMID 25669148›Full record

ArticleMucosal immunology2015

Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques.

Y Fukuyama, Y Yuki, Y Katakai, N Harada, H Takahashi, S Takeda, M Mejima, S Joo, S Kurokawa, S Sawada and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mucosal immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 114 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Human vaccines & immunotherapeutics · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Mucosal vaccines: wisdom from now and then.International immunology · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Y FukuyamaDivision of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
Y Yuki1] Division of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan [2] International Research and Development Center for Mucosal Vaccine, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
Y KatakaiCorporation for Production and Research of Laboratory Primates, Tsukuba, Ibaraki, Japan.
N HaradaPET Center, Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan.
H TakahashiDepartment of Polymer Chemistry, Kyoto University Graduate School of Engineering, Nishikyo-ku, Kyoto, Japan.
S TakedaDepartment of Polymer Chemistry, Kyoto University Graduate School of Engineering, Nishikyo-ku, Kyoto, Japan.
M MejimaDivision of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
S JooDivision of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
S KurokawaDivision of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
S SawadaDepartment of Polymer Chemistry, Kyoto University Graduate School of Engineering, Nishikyo-ku, Kyoto, Japan.
H ShibataTsukuba Primate Research Center, National Institute of Biomedical Innovation, Tsukuba, Ibaraki, Japan.
E J ParkDivision of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
K FujihashiDepartments of Pediatric Dentistry and Microbiology, The Immunobiology Vaccine Center, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
D E BrilesDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Y YasutomiTsukuba Primate Research Center, National Institute of Biomedical Innovation, Tsukuba, Ibaraki, Japan.
H TsukadaPET Center, Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan.
K AkiyoshiDepartment of Polymer Chemistry, Kyoto University Graduate School of Engineering, Nishikyo-ku, Kyoto, Japan.
H Kiyono1] Division of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan [2] International Research and Development Center for Mucosal Vaccine, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
The University of Tokyo · JPKyoto University · JPHamamatsu Photonics (Japan) · JPNational Institute of Biomedical Innovation, Health and Nutrition · JPUniversity of Alabama at Birmingham · USCorporation for Production and Research of Laboratory Primates · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously established a nanosized nasal vaccine delivery system by using a cationic cholesteryl group-bearing pullulan nanogel (cCHP nanogel), which is a universal protein-based antigen-delivery vehicle for adjuvant-free nasal vaccination. In the present study, we examined the central nervous system safety and efficacy of nasal vaccination with our developed cCHP nanogel containing pneumococcal surface protein A (PspA-nanogel) against pneumococcal infection in nonhuman primates. When [(18)F]-labeled PspA-nanogel was nasally administered to a rhesus macaque (Macaca mulatta), longer-term retention of PspA was noted in the nasal cavity when compared with administration of PspA alone. Of importance, no deposition of [(18)F]-PspA was seen in the olfactory bulbs or brain. Nasal PspA-nanogel vaccination effectively induced PspA-specific serum IgG with protective activity and mucosal secretory IgA (SIgA) Ab responses in cynomolgus macaques (Macaca fascicularis). Nasal PspA-nanogel-induced immune responses were mediated through T-helper (Th) 2 and Th17 cytokine responses concomitantly with marked increases in the levels of miR-181a and miR-326 in the serum and respiratory tract tissues, respectively, of the macaques. These results demonstrate that nasal PspA-nanogel vaccination is a safe and effective strategy for the development of a nasal vaccine for the prevention of pneumonia in humans.

Indexed as

NanoparticlesAdministration, IntranasalAnimalsAntibodies, BacterialAntibodies, NeutralizingBacterial ProteinsDrug CarriersFemaleGelsGlucansHumansMacaca fascicularisMaleMicroRNAsPneumonia, PneumococcalStreptococcus pneumoniaeAntibodies, BacterialAntibodies, NeutralizingBacterial ProteinsDrug CarriersGelsGlucansMicroRNAspneumococcal surface protein Apullulan

Identifiers

PMID25669148
PMCPMC4762909
OpenAlexW1986648571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.